2. Harbeck N, Ciruelos E, Jerusalem G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med (2024). 3. Bartsch R, Berghoff AS, F...
LBA18 - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results DESTINY Breast-12研究的主要研究结果:德曲妥珠单抗(T-...
[5]Pernas S, Im S, Hattori M, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study. 2024 A...
2、Nederlof I, et al. Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs). ESMO Congress 2024, LBA11 来源: https://dailyreporter.esmo.org/esmo-congress-2024/breast-cancer/early-stage-immunotherapy-significantly-prol...
[15] Bartsch R, Berghoff AS, Furtner J, et al. Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases. Neuro Oncol. 2024 Jul 4:noae123
日期:2024年9月13日 时间:16:00 - 17:30 主席:Christos Sotiriou (Brussels, Belgium) Karen A. Gelmon (Vancouver, Canada, British Columbia) 地点:Barcelona Auditorium - Hall 2 LBA18 - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or...
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line(1L)treatment for triple-negative breast cancer(TNBC) 依沃西单抗联合化疗一线治疗三阴性乳腺癌(TNBC)的安全性和有效性 汇报讲者:王晓稼 浙江省肿瘤医院 摘要号:348MO ...
张剑教授团队的孟艳春教授代表团队就“A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002/BNT327 in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer”进行了口头报告,了PM8002联合白蛋白结合型紫杉醇治疗三阴性乳腺癌的...
Mini oral session 1: Breast cancer, metastatic 日期:2024年9月15日 时间:08:30 - 10:00 主席:Christos Sotiriou (Brussels, Belgium) Patricia Lorusso (New Haven, United States of America, MI) 地点:Barcelona Auditorium - Hall 2 344MO - ESG401, a novel Trop2 antibody-drug conjugate (ADC), ...
摘要号:VP2-2024 Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial 氟唑帕利±阿帕替尼治疗HER2-转移性乳腺癌患者 (pts) 中携带BRCA1/2突变 (gBRCA1/2m) 的疗效:一项随机 III...